This inhibition profile is particularly intriguing and appealing given that CXCR2-associated cancers are often characterized by the upregulation of one or two CXCR2 ligands (Nagarsheth et al., 2017; Zhang et al., 2020). The gene discussed is CXCR2; the disease is cancer.